KUALA LUMPUR: Hong Seng Consolidated Bhd's (HSCB) wholly-owned subsidiary, HS Bio Supplies Sdn Bhd (HBS) today signed a cooperation framework agreement with Fosun Trade Co Ltd (FTCL), the subsidiary of Hong Kong listed Fosun International Ltd (FIL), to jointly explore opportunities in the Malaysian healthcare sector.
A filing with Bursa Malaysia showed that HSCB views this collaboration positively as it provides HBS a timely opportunity to drive its healthcare business forward particularly in the provision of healthcare related products through the agreement.
HSCB will also be able to expand its customers base to include government and private medical agencies, hospitals, laboratories and others while tapping on the existing private clinics network of eMedAsia Sdn Bhd (eMedAsia), which is currently a 20 per cent associate company of HBS.
HBS is in the midst of acquiring the additional 32 per cent stake in eMedAsia and expected completion in February 2021.
HBS provides pharmaceutical, medical and healthcare supplies such as medicine, medical consumables, bio supplies, medical equipment or devices, test-kits, vaccines, supplements, and other pharmaceutical, medical and healthcare related products as well as healthcare related services in addition to the supply chain management services for the healthcare industry.
The company had on 12 January 2021 obtained an establishment licence issued by the Medical Device Authority, the Ministry of Health Malaysia with a validity period from 12 January 2021 until 11 January 2024 to act as an authorised representative, distributor and importer of medical and healthcare products in Malaysia.
On the other hand, FTCL provides customised trade solution to global clients through its C2M business model to supply chains and global network of quality manufacturers.
Its parent company, FIL is a Fortune 500 company that has total assets of RMB715.7 billion (US$102.6 billion) as of 31 December 2019 and total revenue of RMB143.0 billion (US$20.7 billion) in 2019.